[A combination study of S-1 and docetaxel in patients with head and neck cancer].
We determined the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of drug sequence on toxicities of the combination of S-1 and docetaxel for head and neck cancers. S-1 was administered at the full dose of 80 mg/m2 for two weeks and docetaxel on day 1 according to the following dose escalation schedule: level 1: 40 mg/m2, level 2: 50 mg/m2, and level 3: 60 mg/m2. DLT was observed in two cases of level 3. Although grade 3 leukopenia was observed in level 3, all of the toxicities were not severe. Recommended doses for the next phase evaluation were determined to be 80 mg/m2 of S-1 and 50 mg/m2 of docetaxel. Oral S-1 combination with docetaxel is a feasible and promising combination regimen that is appropriate for an outpatient setting.
Ito
Hiroyuki
H
Dept. of Otolaryngology, Tokyo Medical University, Japan.
Yoshida
Tomoyuki
T
Tokashiki
Ryoji
R
Shimizu
Akira
A
Hiramatsu
Hiroyuki
H
Tsukahara
Kiyoaki
K
Funato
Nobutoshi
N
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D020714:Maximum Tolerated Dose; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid